Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
复制标题
DOI:
10.1093/jnci/djy022
复制
发表时间:
2018-10-01
期刊:
影响因子:
--
通讯作者:
De Preter K
中科院分区:
文献类型:
--
作者:
Depuydt P;Boeva V;Hocking TD;Cannoodt R;Ambros IM;Ambros PF;Asgharzadeh S;Attiyeh EF;Combaret V;Defferrari R;Fischer M;Hero B;Hogarty MD;Irwin MS;Koster J;Kreissman S;Ladenstein R;Lapouble E;Laureys G;London WB;Mazzocco K;Nakagawara A;Noguera R;Ohira M;Park JR;Pötschger U;Theissen J;Tonini GP;Valteau-Couanet D;Varesio L;Versteeg R;Speleman F;Maris JM;Schleiermacher G;De Preter K
Neuroblastoma is characterized by substantial clinical heterogeneity. Despite intensive treatment, the survival rates of high-risk neuroblastoma patients are still disappointingly low. Somatic chromosomal copy number aberrations have been shown to be associated with patient outcome, particularly in low- and intermediate-risk neuroblastoma patients. To improve outcome prediction in high-risk neuroblastoma, we aimed to design a prognostic classification method based on copy number aberrations. In an international collaboration, normalized high-resolution DNA copy number data (arrayCGH and SNP arrays) from 556 high-risk neuroblastomas obtained at diagnosis were collected from nine collaborative groups and segmented using the same method. We applied logistic and Cox proportional hazard regression to identify genomic aberrations associated with poor outcome. In this study, we identified two types of copy number aberrations that are associated with extremely poor outcome. Distal 6q losses were detected in 5.9% of patients and were associated with a 10-year survival probability of only 3.4% (95% confidence interval [CI] = 0.5% to 23.3%, two-sided P = .002). Amplifications of regions not encompassing the MYCN locus were detected in 18.1% of patients and were associated with a 10-year survival probability of only 5.8% (95% CI = 1.5% to 22.2%, two-sided P < .001). Using a unique large copy number data set of high-risk neuroblastoma cases, we identified a small subset of high-risk neuroblastoma patients with extremely low survival probability that might be eligible for inclusion in clinical trials of new therapeutics. The amplicons may also nominate alternative treatments that target the amplified genes.
登录
查看更多内容
影响因子:
30.8
作者:
Eleveld TF;Oldridge DA;Bernard V;Koster J;Colmet Daage L;Diskin SJ;Schild L;Bentahar NB;Bellini A;Chicard M;Lapouble E;Combaret V;Legoix-Né P;Michon J;Pugh TJ;Hart LS;Rader J;Attiyeh EF;Wei JS;Zhang S;Naranjo A;Gastier-Foster JM;Hogarty MD;Asgharzadeh S;Smith MA;Guidry Auvil JM;Watkins TB;Zwijnenburg DA;Ebus ME;van Sluis P;Hakkert A;van Wezel E;van der Schoot CE;Westerhout EM;Schulte JH;Tytgat GA;Dolman ME;Janoueix-Lerosey I;Gerhard DS;Caron HN;Delattre O;Khan J;Versteeg R;Schleiermacher G;Molenaar JJ;Maris JM
通讯作者:
Maris JM
影响因子:
4.7
作者:
Burgess A;Chia KM;Haupt S;Thomas D;Haupt Y;Lim E
通讯作者:
Lim E
影响因子:
11.1
作者:
Ross-Adams H;Lamb AD;Dunning MJ;Halim S;Lindberg J;Massie CM;Egevad LA;Russell R;Ramos-Montoya A;Vowler SL;Sharma NL;Kay J;Whitaker H;Clark J;Hurst R;Gnanapragasam VJ;Shah NC;Warren AY;Cooper CS;Lynch AG;Stark R;Mills IG;Grönberg H;Neal DE;CamCaP Study Group
通讯作者:
CamCaP Study Group
影响因子:
6.4
作者:
Coco, Simona;Theissen, Jessica;Tonini, Gian Paolo
通讯作者:
Tonini, Gian Paolo
影响因子:
5.2
作者:
Peddibhotla, Sirisha;Nagamani, Sandesh C. S.;Cheung, Sau W.
通讯作者:
Cheung, Sau W.